Cytokinetics, Incorporated
CYTK
$38.34
$0.290.76%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.24% | -18.97% | -9.59% | -24.05% | -11.41% |
| Total Depreciation and Amortization | -5.03% | -1.33% | -62.38% | 30.04% | 29.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.66% | 10.70% | 246.53% | 56.45% | 9.48% |
| Change in Net Operating Assets | -623.30% | 79.76% | -7.05% | 567.39% | 140.53% |
| Cash from Operations | -29.12% | -1.63% | 11.44% | -5.50% | 18.47% |
| Capital Expenditure | -116.45% | -- | -1,575.32% | -218.64% | -167.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.78% | 241.96% | 237.89% | -160.54% | -884.15% |
| Cash from Investing | 108.12% | 224.61% | 236.18% | -161.68% | -893.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 6.25% | -209.44% | -1,212.61% | -1,233.64% | -1,257.55% |
| Issuance of Common Stock | -98.92% | -93.79% | -96.17% | 42.45% | 10,870.44% |
| Repurchase of Common Stock | -- | 99.93% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -62.50% | -- | -- | -100.00% | -- |
| Cash from Financing | -90.43% | -95.42% | -98.59% | -93.68% | 14,895.63% |
| Foreign Exchange rate Adjustments | -4,362.50% | -1,100.00% | 1,560.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.44% | -404.62% | 259.80% | -561.32% | 305.15% |